Legato Capital Management LLC Acquires 60,463 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Legato Capital Management LLC grew its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 258.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 83,833 shares of the company’s stock after purchasing an additional 60,463 shares during the quarter. Legato Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $2,941,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Capital World Investors raised its holdings in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares in the last quarter. Jennison Associates LLC raised its holdings in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares during the period. Wellington Management Group LLP raised its holdings in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the period. Finally, Polar Capital Holdings Plc raised its holdings in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after acquiring an additional 393,855 shares during the period. Institutional investors own 89.89% of the company’s stock.

Insider Transactions at NewAmsterdam Pharma

In other news, CEO Michael H. Davidson sold 443,707 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer owned 174,144 shares in the company, valued at approximately $5,790,288. The trade was a 71.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 44,619 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the transaction, the director owned 10,360 shares in the company, valued at approximately $315,151.20. The trade was a 81.16% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,122,805 shares of company stock worth $36,606,033. 12.74% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS opened at $35.44 on Friday. The firm’s 50-day moving average is $32.76 and its 200-day moving average is $34.25. NewAmsterdam Pharma Company N.V. has a 52-week low of $16.78 and a 52-week high of $42.21. The company has a market cap of $4.14 billion, a price-to-earnings ratio of -19.80 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million for the quarter. Equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on NAMS. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Needham & Company LLC lifted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Finally, Guggenheim lifted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.